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Background: It is unclear how retinal ischemia influences the changes of visual acuity, macular sensitivity, macular
thickness, and macular volume after the performance of pars plana vitrectomy (PPV) for macular edema in patients
with central retinal vein occlusion (CRVO).
Methods: Ten patients (10 eyes) with CRVO and macular edema underwent PPV. Retinal ischemia was evaluated
from the area of capillary nonperfusion on fluorescein angiography, and the patients were classified into ischemic
or nonischemic groups. Microperimetry was performed with a Micro Perimeter 1. Macular thickness and volume
were measured by optical coherence tomography.
Results: In both groups, the mean macular thickness within the central 4°, 10°, and 20° fields decreased significantly
from baseline to 3 and 6 months after PPV (all P < 0.05). In the ischemic group, the mean macular sensitivity within
the central 4°, 10°, and 20° fields increased from baseline to 3 and 6 months after PPV, but no significant difference
was observed.
Conclusions: These results suggest that PPV may be effective for improving macular thickness, volume, and sensitivity
in patients with macular edema secondary to ischemic CRVO, although there was no significant difference.Background
Macular edema is the most vision-threatening complica-
tion of central retinal vein occlusion (CRVO). Vascular
endothelial growth factor (VEGF) is thought to have an im-
portant role in the pathogenesis of macular edema [1], and
anti-VEGF therapy has been shown to improve macular
edema over both the short-term and the long-term [2,3].
In addition to intravitreal injection of anti-VEGF agents
[4], macular edema associated with CRVO can be treated
by injection of triamcinolone acetonide [5] or by pars plana
vitrectomy (PPV) [6]. These methods have all been
reported to improve both visual acuity and macular edema.
However, evaluation of visual function from visual acuity
alone is problematic because macular edema also involves
the larger macula area beyond the fovea in most CRVO
patients and measurement of visual acuity only assesses fo-
veal function. Thus, a reproducible method of measuring* Correspondence: noma-hide@umin.ac.jp
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reproduction in any medium, provided the orretinal function is needed to more accurately assess the re-
sponse of macular edema to treatment.
The Micro Perimeter 1 (MP-1) is an instrument that
combines digital fundus imaging with automated perim-
etry [7]. Thus, it allows evaluation of both the fovea and
the entire macular region, unlike measurement of visual
acuity. Recently, we reported that retinal thickness and
retinal volume are correlated with both retinal sensitivity
and best-corrected visual acuity (BCVA) in CRVO
patients who have macular edema [8]. This suggests that
BCVA may be an inadequate parameter for evaluating
the response of macular edema to treatment, while the
functional prognosis may be better assessed by measur-
ing the retinal sensitivity of the fovea and the entire
macular region with the MP-1. In addition, the visual
prognosis of CRVO patients with macular edema treated
by intravitreal bevacizumab was reported to be influ-
enced by retinal ischemia [9]. However, little is known
about the influence of retinal ischemia on retinal sensi-
tivity after performance of PPV for macular edema in
CRVO patients. Therefore, we evaluated the influence oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sitivity, macular thickness, and macular volume after
PPV in CRVO patients with macular edema.
Methods
Subjects
This study was approved by the institutional review
boards of Tokyo Women’s Medical University and
adhered to the tenets of the Declaration of Helsinki.
Written informed consent was obtained from each pa-
tient. Pars plana vitrectomy was performed because it
has been reported that macular edema and visual acuity
can be improved by this procedure in CRVO patients [6].
We retrospectively studied 10 eyes of 10 patients with
macular edema with CRVO who were treated with PPV.
Ten patients (mean age: 71.6 ± 7.2 years; 7 women and 3
men) were included in this uncontrolled study conducted
at the Department of Ophthalmology of Tokyo Women’s
Medical University between May 2009 and July 2011.
Patients were diagnosed as having hypertension if the
systolic blood pressure was ≥140 mm Hg and diastolic
blood pressure was >90 mm Hg, or if the systolic pres-
sure was ≥140 mm Hg at one examination and the dia-
stolic pressure was ≥90 mm Hg on a different day, or if
the patient was already taking antihypertensive medica-
tion. A diagnosis of hyperlipidemia was based on a total
cholesterol≥240 mg/dL, triglycerides≥160 mg/dL, low-
density lipoprotein cholesterol≥130 mg/dL, or use of
cholesterol-lowering medication.
The indications for treatment of macular edema with
PPV were: (1) cystoid macular edema, (2) a foveal thickness
greater than 300 μm, and (3) best-corrected visual acuity
worse than 20/50. The exclusion criteria were (1) previous
ocular surgery, (2) diabetes mellitus with diabetic retinop-
athy, (3) previous macular laser photocoagulation, (4) pre-
vious intravitreal injection of anti-VEGF agents or
triamcinolone acetonide, (5) a history of ocular in-
flammation, (6) marked retinal hemorrhage (including
macular bleeding involving the intrafoveal or subfo-
veal spaces), (7) coexisting ocular disease (i.e., epiret-
inal membrane or glaucoma), and (8) retreatment
during the 6-month follow-up period.
All patients had undergone a comprehensive ophthal-
mologic examination, including best-corrected visual
acuity measurement, intraocular pressure determination,
indirect ophthalmoscopy, and slit-lamp biomicroscopy
with a contact lens before and at 3, and 6 months after
treatment. In addition, retinal sensitivity was investigated
by microperimetry, and retinal thickness and retinal vol-
ume were measured by OCT.
Surgical procedure
Ten patients received pars plana vitrectomy under local
anaesthesia. When PPV was done, all epiretinal materials,the residual cortex, and the posterior hyaloid were
removed from the retinal surface around the macula as
completely as possible with the assistance of triamcinolone
acetonide (the minimum necessary volume was injected
and then was removed as thoroughly as possible at the end
of surgery, because it can influence cystoid macular
edema). Internal limiting membrane (ILM) peeling was not
done because peeling-related retinal injury can have a vari-
able effect on retinal sensitivity, which could have caused
bias in this study. Intraoperative scatter laser photocoagu-
lation to the ischemic region of the retina was not done.
During surgery, iatrogenic peripheral retinal tears did not
occur in any of the patients. Concurrent phacoemulsifica-
tion with intraocular lens insertion into the bag was per-
formed. All of the patients who had cataract surgery were
classified into Emery-Little grades I or II according to the
new World Health Organization Simplified Cataract Grad-
ing System. All patients were followed up for at least
6 months postoperatively. Neovascular glaucoma and iris
neovasculariation were not detected in any of the patients
after follow up for six months, so trabeculectomy or tube
shunt surgery was not performed up to that time.
Fundus examination
As baseline screening, patients underwent ophthalmos-
copy and biomicroscopic examination using a slit-lamp
with a fundus contact lens. They also underwent stand-
ard fundus color photography and fluorescein angiog-
raphy, which was performed with a Topcon TRC-50EX
fundus camera, an image-net system (Tokyo Optical Co.
Ltd., Japan), and a preset lens with a slit-lamp.
A masked grader independently assessed ischemic
retinal vascular occlusion on the fluorescein angio-
grams by measuring the ischemic area of the retina
with the public domain Scion Image program, as
reported previously [10-12]. On digital photographs of
the fundus, the optic disc was outlined with a cursor
and then its area was measured, as was also done for
the nonperfused area of the retina. Then the nonper-
fused area was divided by the disc area to calculate
the severity of retinal ischemia. If the non-perfused
area divided by the disc area gave a value of 10 or
more, this was defined as indicating the presence of
retinal ischemia (ischemic CRVO group) [13-15].
Measurement of BCVA
Each patient underwent measurement of best-corrected
visual acuity (BCVA) with an SC-2000 System chart
(Nidek, Gamagori, Japan). BCVA was measured in deci-
mal units on a Landolt chart by the orthopticists. The
chart brightness was set at 80–320 cd/m2, and chart
contrast was more than 74%. The results were converted
to the logarithm of the minimum angle of resolution
scale (log MAR).
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OCT was performed with an instrument from Zeiss-
Humphrey Ophthalmic Systems (Zeiss Stratus OCT3,
Carl Zeiss Meditec, Dublin, CA, USA) to measure the fo-
veal thickness. At each visit, all patients underwent Stratus
OCT examination in the vertical cross-section with the in-
strument centered on the fovea and in the fast macular
thickness mode. On these views, retinal thickness was
defined as the distance between the inner surface of the
neurosensory retina and the retinal pigment epithelium.
Foveal thickness was calculated as the average retinal thick-
ness within a circle of 500-μm radius centered on the
fovea. A retinal thickness map and retinal volume map
were obtained by scanning 6×6 mm (20°×20°) areas of the
macular region, which was divided into the following nine
subfields: 1) fovea, 2) superior inner macula, 3) nasal inner
macula, 4) inferior inner macula, 5) temporal inner macula,
6) superior outer macula, 7) nasal outer macula, 8) inferior
outer macula, and 9) temporal outer macula [8]. The dia-
meters of the central, inner, and outer circles were 1, 3,
and 6 mm, respectively. In each region, measurement of
retinal thickness and volume was automatically performed
by computer software. The mean macular thickness at the
one subfield (fovea) covering the central 1×1 mm (4°×4°),
at five subfields (fovea, superior inner, nasal inner, inferior
inner, and temporal inner) covering the central 3×3 mm
(10°×10°), and at all nine subfields covering the entire cen-
tral 6×6 mm (20°×20°) were thus determined.
Functional mapping by microperimetry
Microperimetry with the MP-1 (Nidek, Gamagori, Japan)
is performed using an infrared fundus camera with a liquid
crystal display controlled by special software. The MP-1
software contains an automatic tracking system for fundus
movements; this evaluates every acquired frame for shifts
in the x and y directions of the fundus with respect to a
reference frame obtained by an infrared camera at the be-
ginning of the examination. Each patient underwentTable 1 Baseline clinical features of the ischemic and nonisch




Systolic blood pressure (mmHg) 137±23‡
Diastolic blood pressure (mmHg) 78±6‡
Hyperlipidemia 1
Duration of CRVO (months) 4.3±2.3‡
Visual acuity (log MAR) 1.26 ± 0.41‡ (range; 1.0 to
Cataract (Emery-Little grade) 1.66 ± 0.40‡
CRVO = central retinal vein occlusion; log MAR = logarithm of the minimum angle o
‡Mean ± standard deviation (SD).fundus-monitored microperimetry with the MP-1 system
(Nidek, Gamagori, Japan). Its software performs automatic
tracking of fundus movements and evaluates every frame
acquired for fundus shift in the x and y directions relative
to a reference frame obtained with an infrared camera at
the beginning of the examination. Microperimetry settings
were identical for all examinations: Goldmann III stimuli
were presented in random order according to a 4-2-1
double staircase strategy. The stimulus intensity ranged
from 0 to 20 decibels (dB) (0 dB corresponded to the
strongest signal intensity of 127 cd/m2) in 1-dB steps, and
the duration of each stimulus was 200 ms. The fixation tar-
get was varied in size according to the patient’s visual acu-
ity. Retinal sensitivity maps were obtained by using the
macula 20 degrees program of the MP-1. During the exam-
ination, background illumination was set at 1.27 cd/m2.
Mean retinal sensitivity was calculated from the sensitivity
for each of nine subfields on the retinal map generated by
OCT. The mean macular sensitivities at the five locations
covering the central 4° field, at 29 locations covering the
central 10° field (five subfields; fovea, superior inner, nasal
inner, inferior inner, and temporal inner), and at the 57
locations covering the entire central 20° field (all nine sub-
fields) were thus determined.
Statistical analysis
All analyses were performed with SAS System 9.1 soft-
ware (SAS Institute Inc., Cary, North Carolina, USA).
Results are presented as the mean ± SD or as the fre-
quency. One-way repeated measures analysis of variance
(ANOVA) was used to evaluate the changes of visual
acuity, macular sensitivity, macular thickness, and macu-
lar volume. Two-tailed P values of less than 0.05 were
considered to indicate statistical significance.
Results
The characteristics of the ischemic and nonischemic
groups are summarized in Table 1. Among the 10emic groups








2.0) 0.59 ± 0.38‡ (range; 0.30 to 1.15) 0.031
1.25 ± 0.28‡ 0.117
f resolution scale;
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group and 4 to the nonischemic group. There were no
significant differences between the two groups with re-
gard to the mean age, female/male ratio, prevalence of
hypertension, prevalence of hyperlipidemia, and duration
of CRVO (P = 0.133, P = 0.500, P = 0.778, P = 0.190, and
P = 0.061, respectively).
In the ischemic group, the mean macular thickness
within the central 4°, 10°, and 20° fields showed a signifi-
cant decrease from baseline to 3 and 6 months afterFigure 1 Changes of the mean macular thickness (A-C) after pars plan
ischemic group, the mean macular thickness within the central 4°, 10°, and
after PPV (P = 0.007, P = 0.012, and P = 0.040, respectively). In the nonischem
20° fields also decreased significantly from baseline to 3 and 6 months aftePPV (P = 0.007, P = 0.012, and P = 0.040, respectively)
(Figure 1A-C). In the nonischemic group, the mean macu-
lar thickness within the central 4°, 10°, and 20° fields also
showed a significant decrease from baseline to 3 and
6 months after PPV (P = 0.002, P = 0.007, and P = 0.030, re-
spectively) (Figure 1A-C).
The visual acuity of the ischemic group improved from
baseline to 3 and 6 months after PPV, although not signifi-
cantly (P = 0.569) (Figure 2). Likewise, the visual acuity of
the nonischemic group showed some improvement froma vitrectomy (PPV) in CRVO patients with macular edema. In the
20° fields decreased significantly from baseline to 3 and 6 months
ic group, the mean macular thickness within the central 4°, 10°, and
r PPV (P = 0.002, P = 0.007, and P = 0.030, respectively).
Figure 2 Changes of mean visual acuity after pars plana
vitrectomy (PPV) in CRVO patients with macular edema. In the
ischemic group, visual acuity improved from baseline to 3 and
6 months after PPV, although not significantly (P = 0.569). Likewise,
the nonischemic group showed improvement of visual acuity from
baseline to 3 and 6 months after PPV, although it was not
significant (P = 0.359).
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not significant (P = 0.359) (Figure 2).
In the ischemic group, the mean macular sensitiv-
ity within the central 4°, 10°, and 20° fields increased
from baseline to 3 and 6 months after PPV, although
the changes were not significant (P = 0.233, P = 0.179,
and P = 0.247, respectively) (Figure 3A-C). In the
nonischemic group, however, mean macular sensitiv-
ity within the central 4°, 10°, and 20° fields was not
increased from baseline to 3 and 6 months after
PPV (P = 0.620, P = 0.226, and P = 0.321, respectively)
(Figure 3A-C).
Improvement of visual acuity and macular sensitivity
was calculated by subtracting the postoperative value from
the preoperative value. Improvement of macular edema
was evaluated by calculating the percent change of macular
edema (%ΔME) as follows: %ΔME= (MEpr−MEpo)/MEpr ×
100 = (1−MEpo/MEpr) × 100, where MEpr and MEpo are
the macular thickness and volume before vitrectomy and
6 months after surgery, respectively. It was found that
the duration of CRVO had no significant influence on
the improvement of visual acuity (ρ = 0.18, P = 0.619);
the improvement of macular sensitivity within the
central 4° field (ρ = 0.20, P = 0.579), 10° field (ρ = 0.31,
P = 0.376), or 20° field (ρ = 0.33, P = 0.346); the im-
provement of macular thickness within the central 4°
field (ρ = −0.09, P = 0.806), 10° field (ρ = −0.20, P =
0.578), or 20° field (ρ = −0.22, P = 0.538); and the im-
provement of macular volume within the central 4° d(ρ = −0.16, P = 0.665), 10° field (ρ = −0.17, P = 0.634), or 20°
field (ρ = −0.20, P = 0.580).
Discussion
The present study demonstrated that the mean
macular thickness within the central 4°, 10°, and 20°
fields decreased significantly from before PPV to 3
and 6 months after PPV in patients with either is-
chemic or nonischemic CRVO. It has been reported
that an increase of oxygen tension in the inner retina
could be an important effect of PPV [16,17]. If the
retinal oxygen tension increases after PPV, macular
edema would decrease for the following two reasons:
1) an increase of oxygen tension would reduce VEGF
production and decrease vascular permeability to re-
duce edema, and 2) an increase of oxygen tension
would alleviate autoregulatory arteriolar vasoconstric-
tion and thus lower the hydrostatic pressure in the
retinal capillaries and venules, so that decreased
water flux from the vascular compartment to the tis-
sue compartment would reduce edema according to
Starling’s law. Furthermore, the increase of oxygen
tension in the inner retina seems to persist over the
long term after PPV, so surgery may have a signifi-
cant influence on macular edema. We previously
reported that the vitreous fluid levels of various in-
flammatory factors were elevated in CRVO patients
[1,18]. If PPV reduces the intraocular levels of in-
flammatory factors, this may be another mechanism
by which surgery improves macular edema in CRVO
patients. Such a mechanism is supported by our re-
port that a high vitreous VEGF level was associated
with greater improvement of macular edema after
PPV [19].
Regarding macular sensitivity, we found that the mean
macular sensitivity within the central 4°, 10°, and 20°
fields was increased from baseline to 3 and 6 months
after PPV in the ischemic group (although not signifi-
cantly), while it did not increase in the nonischemic
group. Fluid currents carrying oxygen from well-
perfused to ischemic areas of the retina may be
increased by PPV, improving oxygenation of the ische-
mic inner retina and raising the local oxygen tension
[16,17]. An increase of oxygen tension in the inner ret-
ina after PPV could reverse functional impairment of
photoreceptor cells, resulting in improvement of macu-
lar sensitivity. In summary, our results suggest that PPV
may be more effective for improving retinal sensitivity
over the larger macular area in patients with ischemic
CRVO than in those with nonischemic CRVO.
Anti-VEGF therapy was recently reported to improve
macular edema in CRVO patients, but most of the sub-
jects had nonischemic CRVO [4]. In another study, anti-
VEGF therapy was found to be effective for macular
Figure 3 Changes of mean macular sensitivity (A-C) after pars plana vitrectomy (PPV) in CRVO patients with macular edema. In the ischemic
group, the mean macular sensitivity within the central 4°, 10°, and 20° fields increased from baseline to 3 and 6 months after PPV, although not
significantly (P = 0.233, P = 0.179, and P = 0.247, respectively). In the nonischemic group, however, the mean macular sensitivity within the central 4°, 10°,
and 20° fields was not increased from baseline to 3 and 6 months after PPV (P = 0.620, P = 0.226, and P = 0.321, respectively).
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sion, but not in those with ischemic retinal vein occlu-
sion [2]. Taken together, these findings and our results
suggest that if CRVO patients have retinal ischemia, a
new strategy of performing PPV if anti-VEGF therapy
fails could be considered from the viewpoint of improv-
ing macular sensitivity. However, the present study had
several limitations, including a short follow-up period,
small sample size, and no control group. Accordingly, a
randomized, prospective clinical trial of these therapieswould be required to confirm the efficacy of PPV for
macular edema in patients with ischemic CRVO.
Conclusions
Macular sensitivity within the central 4°, 10°, and 20°
fields was improved from baseline to 3 and 6 months
after PPV in patients with ischemic CRVO, but no sig-
nificant difference was observed. These results suggest
that PPV may be effective for improving macular edema
and macular sensitivity in patients with ischemic CRVO.
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